Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:36 p.m.

    📋 MIRATI THERAPEUTICS, INC. (MRTX) - Financial Results

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 16:04:23

    Event Type: Financial Results

    Event Details:

    Mirati Therapeutics Inc (was acquisied by Bristol Myers Squibb (NYSE: BMY) on 23/01/2024) (MRTX) Reports Q3 2022 Financial Results Mirati Therapeutics Inc (was acquisied by Bristol Myers Squibb (NYSE: BMY) on 23/01/2024) (MRTX) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 5362
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 1181328
      • targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook.2Forward Looking StatementsThis press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation adagrasib (selective KRASG12C inhibitor), sitravatinib (TAM receptor inhibitor), MRTX1719

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Current Assets Property Equipment Net 17.16K 15.82K $1.34K +8.46%
    Current Liabilities Accounts Payable 24.27K 24.27K $0.00 +0.00%
    Current Liabilities Accrued Liabilities 94.88K 108.50K $-13.62K -12.55%
    Expenses Loss From Operations -164.19K -361.42K $197.24K +54.57%
    Expenses Total Other Income Expense -2.24K -3.41K $1.16K +34.15%
    Net Loss -166.43K -166.43K $0.00 +0.00%
    Net Loss Per Share -3.23 -3.23 $0.00 +0.00%
    Property and Equipment, Net 15.82K 15.82K $0.00 +0.00%
    Accounts Payable 35.16K 35.16K $0.00 +0.00%
    Accrued Liabilities 108.50K 108.50K $0.00 +0.00%
    Revenue 5.36K 5.36K $0.00 +0.00%
    Loss from Operations -164.19K -361.42K $197.24K +54.57%
    Net Loss -166.43K -166.43K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Mirati Therapeutics Inc (was acquisied by Bristol Myers Squibb (NYSE: BMY) on 23/01/2024)
    • CIK: 0001576263
    • Ticker Symbol: MRTX
    • Period End Date: 2022-08-03
    • Document Type: 8-K

Search

News categories